<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40221">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582775</url>
  </required_header>
  <id_info>
    <org_study_id>2015LS076</org_study_id>
    <nct_id>NCT02582775</nct_id>
  </id_info>
  <brief_title>MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs</brief_title>
  <official_title>MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-institution, phase II study to determine the event-free survival at 1 year
      post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related
      donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the
      biochemical correction of severe epidermolysis bullosa (EB).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>An event defined as death or a 50% increase in a patient's IScoreEB from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change of a patient's iscorEB</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>iscorEB surveys are a validated, standard of care tool used to assess disease status in patients with Epidermolysis Bullosa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>180 days post-transplant</time_frame>
    <description>Cumulative incidence will be used to estimate the probability of relapse treating non-relapse death as a competing risk and transplant-related mortality conversely treating relapse as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Measured by the Lansky score (10-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Measured by the Lansky score (10-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism in the Skin</measure>
    <time_frame>Day 28 post-transplant</time_frame>
    <description>Donor engraftment in skin assessed by competitive polymerase-chain-reaction analysis of polymorphic variable-number tandem-repeat regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism in the Skin</measure>
    <time_frame>Day 100 post-transplant</time_frame>
    <description>Donor engraftment in skin assessed by competitive polymerase-chain-reaction analysis of polymorphic variable-number tandem-repeat regions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>anti-thymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 IV over 60 minutes days -6 through day -2</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>200 cGy BID for a total dose of 400cGy</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow infusion</intervention_name>
    <description>Bone marrow infusion on Day 0</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors)</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35</description>
    <arm_group_label>Hematopoietic cell transplant alone</arm_group_label>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor mesenchymal stem cell infusions</intervention_name>
    <description>Day 60, 100 and 180 (collected during donor BM harvest for graft)</description>
    <arm_group_label>Hematopoietic cell transplant plus serial MSC infusions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe form of EB characterized by collagen, laminin, integrin, keratin
             or plakin deficiency (by immunofluorescence staining with protein specific antibodies
             or Western blotting and by mutation analysis).

          -  An available related donor (HLA identical, mismatched or haploidentical) or matched
             unrelated donor

          -  Adequate renal, hepatic, cardiac and pulmonary function

        Exclusion Criteria:

          -  Evidence of HIV infection or known HIV positive serology

          -  Current active serious infection

          -  Diagnosis of squamous cell carcinoma

          -  Donor with EB

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakub Tolar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson, RN</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center and Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson, RN</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
    <investigator>
      <last_name>Jakub Tolar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>October 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
